Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

COVID-19 Dents Biocon Ahead Of Insulin Opportunity

Pandemic-Related R&D Underway, UAE JV Wound Up

May 19 2020

• By Anju Ghangurde

India_Fist_Coronavirus — Biocon Confident Of Recovery Soon Amid Pandemic Challenges • Source: Shutterstock

Related Content

Biocon Biologics Gets True North Investment

Jan 07 2020

Mylan Is Only Just Beginning Its Biosimilars Journey

May 14 2020

Mylan Beats Sanofi On Lantus Patent

Mar 16 2020

Mylan Pursues ‘Market First’ Playbook, Partners Lupin For Enbrel Biosimilar

Jun 29 2018

Biocon Biologics Eyes $1bn In Sales As Q2 Revenues Jump 40%

Oct 29 2019

Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Jan 27 2020

Biocon Rings In 2020 With Gusto, PE Investment In Biologics Arm

Jan 07 2020

String Of Positives For Lupin Lifts Outlook

May 06 2020

Related Companies

Biocon, Ltd.

Sanofi

Viatris Inc.

Lupin Limited

Amgen, Inc.

Pfizer Inc.

Additional Topics

India Asia Pacific Sales & Earnings Biosimilars Coronavirus COVID-19 Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window